Cervical cancer screening programme: annual statistics

Suomeksi

På Svenska

Screening programme overview

– The national cervical cancer screening programme has been running since the 1970s. In 2024 the screening method was either HPV-testing (92%) or Pap testing (8%) depending on the wellbeing services county.

– The target population, i.e., ages 30 to 65, were invited for routine screening at ages divisible by five. In some municipalities those aged 25 were also invited. In addition, those who had a mild positive screening result (HPV-positivity, ASC-US, LSIL) in the previous screening round and were not referred to further examinations, received an invitation for risk group screening.

– 280,812 persons were drawn from the Digital and Population Data Services Agency database for the screening invitation. An invitation may not be sent, for example due to a missing address resulting from a non-disclosure restriction.

– Out of the target population in 2024, 73% attended screening. In routine screening 5.6% were recommended risk group screening and 1.2% were referred for further examinations. In risk group screening 1.3% received a recommendation to another risk group screen and 44.2% were referred to further examinations.

– Based on the colposcopies performed as further examinations, altogether 43 cervical cancers and 1,448 severe precancers were detected.

Whole country

Screening process

2024

Age group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30	35723	23907	66.9	2457	10.3	662	2.8	565	85.3	262	46.4
35	36398	25406	69.8	1768	7.0	434	1.7	370	85.3	177	47.8
40	36653	26654	72.7	1526	5.7	374	1.4	314	84.0	133	42.4
45	34415	25958	75.4	1269	4.9	294	1.1	249	84.7	80	32.1
50	32313	24838	76.9	1224	4.9	225	0.9	192	85.3	53	27.6
55	32680	24907	76.2	1090	4.4	164	0.7	134	81.7	38	28.4
60	36807	27826	75.6	1110	4.0	152	0.5	132	86.8	25	18.9
65	35823	26841	74.9	1009	3.8	140	0.5	115	82.1	28	24.3
Total	280812	206337	73.5	11453	5.6	2445	1.2	2071	84.7	796	38.4

Risk group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30-34	2442	1942	79.5	18	0.9	994	51.2	841	84.6	223	26.5
35-39	1646	1311	79.6	16	1.2	596	45.5	504	84.6	126	25.0
40-44	1554	1255	80.8	22	1.8	576	45.9	502	87.2	139	27.7
45-49	1292	1048	81.1	17	1.6	421	40.2	355	84.3	74	20.8
50-54	1166	993	85.2	13	1.3	365	36.8	317	86.8	44	13.9
55-59	1197	1053	88.0	14	1.3	425	40.4	366	86.1	36	9.8
60-64	1102	948	86.0	10	1.1	417	44.0	345	82.7	31	9.0
65-69	899	791	88.0	13	1.6	338	42.7	287	84.9	22	7.7
Total	11298	9341	82.7	123	1.3	4132	44.2	3517	85.1	695	19.8

2023

Age group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30	35085	23063	65.7	2262	9.8	596	2.6	545	91.4	241	44.2
35	35710	24668	69.1	1681	6.8	438	1.8	407	92.9	195	47.9
40	36523	26551	72.7	1462	5.5	381	1.4	362	95.0	175	48.3
45	33924	25410	74.9	1313	5.2	298	1.2	271	90.9	104	38.4
50	29058	22381	77.0	1116	5.0	223	1.0	199	89.2	70	35.2
55	35104	26619	75.8	1191	4.5	200	0.8	173	86.5	44	25.4
60	37155	28063	75.5	1097	3.9	191	0.7	172	90.1	48	27.9
65	34808	26071	74.9	931	3.6	141	0.5	125	88.7	37	29.6
Total	277367	202826	73.1	11053	5.4	2468	1.2	2254	91.3	914	40.6

Risk group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30-34	2170	1745	80.4	17	1.0	874	50.1	763	87.3	234	30.7
35-39	1390	1098	79.0	14	1.3	537	48.9	468	87.2	150	32.1
40-44	1250	1007	80.6	10	1.0	437	43.4	379	86.7	123	32.5
45-49	1135	921	81.1	17	1.8	331	35.9	283	85.5	83	29.3
50-54	1102	933	84.7	13	1.4	363	38.9	320	88.2	38	11.9
55-59	1104	951	86.1	15	1.6	380	40.0	336	88.4	36	10.7
60-64	963	842	87.4	16	1.9	377	44.8	318	84.4	32	10.1
65-69	449	403	89.8	1	0.2	198	49.1	173	87.4	16	9.2
Total	9563	7900	82.6	103	1.3	3497	44.3	3040	86.9	712	23.4

2022

Age group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30	35821	22818	63.7	2295	10.1	467	2.0	453	97.0	228	50.3
35	33470	22638	67.6	1524	6.7	370	1.6	363	98.1	189	52.1
40	35724	25723	72.0	1509	5.9	353	1.4	342	96.9	167	48.8
45	34273	25436	74.2	1268	5.0	292	1.1	281	96.2	129	45.9
50	30100	22833	75.9	1164	5.1	201	0.9	191	95.0	57	29.8
55	36015	27228	75.6	1201	4.4	178	0.7	172	96.6	47	27.3
60	36879	27761	75.3	1095	3.9	142	0.5	136	95.8	31	22.8
65	36491	27304	74.8	888	3.3	114	0.4	112	98.2	28	25.0
Total	278773	201741	72.4	10944	5.4	2117	1.0	2050	96.8	876	42.7

Risk group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30-34	2528	1889	74.7	20	1.1	917	48.5	876	95.5	251	28.7
35-39	1713	1305	76.2	14	1.1	604	46.3	586	97.0	185	31.6
40-44	1385	1078	77.8	25	2.3	442	41.0	428	96.8	131	30.6
45-49	1260	988	78.4	27	2.7	378	38.3	368	97.4	92	25.0
50-54	1191	962	80.8	28	2.9	334	34.7	319	95.5	56	17.6
55-59	1201	999	83.2	32	3.2	350	35.0	334	95.4	36	10.8
60-64	1050	858	81.7	22	2.6	324	37.8	310	95.7	38	12.3
65-69	452	386	85.4	0	0.0	162	42.0	156	96.3	16	10.3
Total	10780	8465	78.5	168	2.0	3511	41.5	3377	96.2	805	23.8

2021

Age group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30	35045	22911	65.4	2461	10.7	540	2.4	502	93.0	255	50.8
35	33512	22995	68.6	1614	7.0	392	1.7	355	90.6	206	58.0
40	34329	25084	73.1	1425	5.7	305	1.2	281	92.1	149	53.0
45	34064	25488	74.8	1306	5.1	269	1.1	245	91.1	118	48.2
50	31245	23897	76.5	1207	5.1	196	0.8	183	93.4	60	32.8
55	36243	27470	75.8	1232	4.5	182	0.7	160	87.9	63	39.4
60	36791	27918	75.9	1036	3.7	118	0.4	101	85.6	38	37.6
65	15864	11674	73.6	441	3.8	42	0.4	38	90.5	11	28.9
Total	257093	187437	72.9	10722	5.7	2044	1.1	1865	91.2	900	48.3

Risk group screening

Age group	Invited	Attended (of invited)		Follow-up recommendation (of those who participated)		Referral to colposcopy (of those who participated)		Attended colposcopy (of those referred)		Histological HSIL or worse (of those who had colposcopy)
	N	N	%	N	%	N	%	N	%	N	%
30-34	2158	1706	79.1	52	3.0	754	44.2	733	97.2	214	29.2
35-39	1770	1431	80.8	84	5.9	517	36.1	505	97.7	151	29.9
40-44	1547	1263	81.6	73	5.8	414	32.8	392	94.7	118	30.1
45-49	1454	1214	83.5	56	4.6	304	25.0	291	95.7	78	26.8
50-54	1475	1219	82.6	78	6.4	284	23.3	279	98.2	53	19.0
55-59	1269	1090	85.9	57	5.2	298	27.3	288	96.6	29	10.1
60-64	1150	976	84.9	69	7.1	312	32.0	296	94.9	25	8.4
65-69	461	391	84.8	15	3.8	133	34.0	121	91.0	12	9.9
Total	11284	9290	82.3	484	5.2	3016	32.5	2905	96.3	680	23.4